Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia | Future Oncology
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study | Leukemia
Frontiers | Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia
Adult myeloid leukaemias: current and future treatments - The Pharmaceutical Journal
352-Consolidation HiDAC (cytarabine) 1,3,5 | eviQ
Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - ScienceDirect
Fernand Bteich on Twitter: "13/ Typical induction regimen is 7+3. Total is 7 days with 3 days of overlap. 7 days of cytarabine infusion. 3 days of anthracycline infusion (daunorubicin or idarubicin).
Melphalan and Cytarabine as a Salvage Therapy in Children with Relapsed or Refractory Acute Leukemia
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial - The
Genetic factors influencing cytarabine therapy | Pharmacogenomics
Acute Leukemias
Structural insights into mutagenicity of anticancer nucleoside analog cytarabine during replication by DNA polymerase η | Scientific Reports
Cytarabine | C9H13N3O5 - PubChem
Improved chemotherapy modeling with RAG-based immune deficient mice | PLOS ONE
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
Acute myeloid leukemia—Major progress over four decades and glimpses into the future - Kantarjian - 2016 - American Journal of Hematology - Wiley Online Library
AML Refractory to 1 Cycle of High-Dose Cytarabine-Based Induction Chemotherapy
Cancers | Free Full-Text | Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers
Dexamethasone Sensitizes Acute Monocytic Leukemia Cells to Ara-C by Upregulating FKBP51 - Frontiers
Flowchart of regimen consisting of cladribine, cytarabine and etoposide... | Download Scientific Diagram
Cytarabine - Wikipedia
Chemotherapy dosing schedule. The schedule for ARA-C (200 mg/m 2 /d),... | Download Scientific Diagram
Ferrata Storti Foundation
Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene: Molecular Therapy
Mathematical Models for the Influence of Cytarabine on White Blood Cell Dynamics in Acute Myeloid Leukemia | bioRxiv
